Michael Sansoterra

"Novo has struggled... we think that's still the best positioned player I think in April you'll see. Or for GLYBURIDE which is ELI LILLY'S ORAL FOR ZEPBOUND. That should really take some market share. Really set a pricing floor and probably expand nicely into Medicare." The introduction of an oral GLP-1 weight loss drug will provide a significant competitive advantage over injectable alternatives, allowing the company to steal market share from struggling competitors and unlock a massive new revenue stream through government-funded Medicare coverage. LONG due to dominant positioning in the GLP-1 space and major upcoming catalysts that expand the total addressable market. Clinical trial setbacks for the oral pill, regulatory hurdles preventing Medicare inclusion, or intense pricing pressure from competitors.

"NVIDIA in particular, the one trading sideways for six months... was 38 times forward earnings. Now it's a market multiple 20 times 21 times trading earnings growing 60%... The tech winners in the AI chain NVIDIA is one PALANTIR and software is another." The combination of sideways price action and massive earnings growth has compressed valuation multiples to attractive levels. These AI winners will continue to beat expectations, forcing the market to look past short-term macro shocks and re-rate the stocks higher. LONG because the underlying earnings growth of 60%+ provides a strong fundamental floor at current market multiples. Prolonged geopolitical conflicts or severe oil price spikes could damage consumer sentiment and derail the broader risk-on trade.

Rather than chase volatile, super-high memory stocks, he wants to buy the tool maker ASML, the king, to take advantage of DRAM pricing: the 2026 to 2028 DRAM capacity expansion leaves ASML perfectly situated to profit, it can be bought at a reasonable price, and he expects it to beat expectations over the next few years amid sell-side upgrades.